Gilead’s Liver Drug Wins FDA Approval, to Cost $12,606 a Month

Gilead Sciences Inc. won approval from US regulators for Livdelzi, a liver disease drug the company acquired with its $4.3 billion purchase of CymaBay Therapeutics earlier this year.

Livdelzi, a once-daily pill, will cost $12,606 for a 30-day supply, a Gilead spokesperson said. The company anticipates that most insurers will cover the drug.

The drug treats a rare disease that damages the liver’s bile ducts, which can cause liver failure. About 130,000 people in the US, mostly women, suffer from the disease, according to Gilead. Other treatments can offer relief but don’t work for all patients.

Gilead has long focused ...